RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00055227.xml
Nephrologie aktuell 2023; 27(05): 216-220
DOI: 10.1055/a-2013-6622
DOI: 10.1055/a-2013-6622
Schwerpunkt
Nephrologie
LDL-C-Senkung bei Dialysepatienten
Therapie jenseits der Evidenz?
ZUSAMMENFASSUNG
Patienten, die aufgrund einer schweren Nierenerkrankung auf eine Dialyse angewiesen sind, haben ein hohes Risiko für Herz-Kreislauf-Erkrankungen. Häufig leiden diese Patienten u. a. auch an Bluthochdruck, Fettstoffwechselstörungen oder Diabetes mellitus. Ob aber in diesem Zusammenhang die Behandlung von Dialysepatienten mit Statinen gerechtfertigt ist, ist weiterhin umstritten, da in der Vergangenheit randomisierte Studien bei diesen Patienten deren Nutzen nicht belegen konnten. Ein differenzierter Blick zeigt jedoch, dass diese Frage nicht einfach zu beantworten ist. Entgegen dem Anschein gibt es Hinweise, dass selbst Dialysepatienten noch unter bestimmten Voraussetzungen von der Therapie mit Statinen oder anderen lipidsenkenden Maßnahmen zu profitieren scheinen.
Publikationsverlauf
Artikel online veröffentlicht:
08. Juni 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Sarnak MJ, Levey AS, Schoolwerth AC. et al Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169 DOI: 10.1161/01.CIR.0000095676.90936.80.
- 2 Schneider MP, Hilgers KF. [How to Retard Progression of Chronic Kidney Disease]. Dtsch Med Wochenschr 2017; 142: 1282-1289 DOI: 10.1055/s-0042-115782.
- 3 Go AS, Chertow GM, Fan D. et al Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305 DOI: 10.1056/NEJMoa041031.
- 4 Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol 2011; 07: 385-397 DOI: 10.1038/nrneph.2011.62.
- 5 Praschberger M, Hermann M, Wanner J. et al The uremic toxin indoxyl sulfate acts as a pro- or antioxidant on LDL oxidation. Free Radic Biol Med 2014; 75: S36 DOI: 10.1016/j.freeradbiomed.2014.10.778.
- 6 Zewinger S, Kleber ME, Rohrer L. et al Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J 2017; 38: 1597-1607 DOI: 10.1093/eurheartj/ehx118.
- 7 Hobson S, de Loor H, Kublickiene K. et al Lipid profile is negatively associated with uremic toxins in patients with kidney failure–A Tri-National Cohort. Toxins (Basel) 2022; 14: 412 DOI: 10.3390/toxins14060412.
- 8 Vanholder R, Pletinck A, Schepers E. et al Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel) 2018; 10: 33 DOI: 10.3390/toxins10010033.
- 9 Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309 DOI: 10.1038/ki.2014.31.
- 10 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015; 161: 161-172 DOI: 10.1016/j.cell.2015.01.036.
- 11 Sharp Collaborative Group Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160: 785-794.e10 DOI: 10.1016/j.ahj.2010.08.012.
- 12 Rahman M, Yang W, Akkina S. et al Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol 2014; 09: 1190-1198 DOI: 10.2215/CJN.09320913.
- 13 Wang N, Fulcher J, Abeysuriya N. et al Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327037 participants. Lancet Diabetes Endocrinol 2020; 08: 36-49 DOI: 10.1016/S2213-8587(19)30388-2.
- 14 Mathew RO, Maron DJ, Anthopolos R. et al Guideline-directed medical therapy attainment and outcomes in dialysis-requiring versus nondialysis chronic kidney disease in the ISCHEMIA-CKD trial. Circ Cardiovasc Qual Outcomes 2022; 15: e008995 DOI: 10.1161/CIRCOUTCOMES.122.008995.
- 15 Wanner C, Krane V, Marz W. et al Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 DOI: 10.1056/NEJMoa043545.
- 16 Fellstrom BC, Jardine AG, Schmieder RE. et al Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407 DOI: 10.1056/NEJMoa0810177.
- 17 Marz W, Genser B, Drechsler C. et al Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 06: 1316-1325 DOI: 10.2215/CJN.09121010.
- 18 Baigent C, Landray MJ, Reith C. et al The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192 DOI: 10.1016/S0140-6736(11)60739-3.
- 19 Khan SU, Riaz H, Rahman H. et al Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: a systematic review and meta-analysis. J Clin Lipidol 2019; 13: 538-549 DOI: 10.1016/j.jacl.2019.05.014.
- 20 Mafham M, Haynes R. PCSK9 inhibition: ready for prime time in CKD?. Kidney Int 2018; 93: 1267-1269 DOI: 10.1016/j.kint.2018.01.030.
- 21 Toth PP, Dwyer JP, Cannon CP. et al Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018; 93: 1397-1408 DOI: 10.1016/j.kint.2017.12.011.
- 22 Schwartz GG, Steg PG, Szarek M. et al Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097-2107 DOI: 10.1056/NEJMoa1801174.
- 23 Zheng-Lin B, Ortiz A. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs 2018; 78: 215-229 DOI: 10.1007/s40265-017-0858-2.
- 24 Schmit D, Fliser D, Speer T. Proprotein convertase subtilisin/kexin type 9 in kidney disease. Nephrol Dial Transplant 2019; 34: 1266-1271 DOI: 10.1093/ndt/gfz122.
- 25 Lamb YN. Inclisiran: first approval. Drugs 2021; 81: 389-395 DOI: 10.1007/s40265-021-01473-6.
- 26 Wright RS, Collins MG, Stoekenbroek RM. et al Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc 2020; 95: 77-89 DOI: 10.1016/j.mayocp.2019.08.021.
- 27 Ferro CJ, Mark PB, Kanbay M. et al Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 2018; 14: 727-749 DOI: 10.1038/s41581-018-0072-9.
- 28 Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205 DOI: 10.1016/j.atherosclerosis.2019.08.014.